Using AI for Campaign Analysis Without Exposing Sensitive Data
A data-classification gate and safe substitution workflow for using AI tools on pharma campaign data without exposing health or confidential information.
The short answer
AI tools can speed up campaign analysis: spotting trends, writing queries, building charts, and drafting summaries. But pharma campaign data can include health-related information, confidential business data, and partner data under contract restrictions. Putting that data into the wrong tool can create privacy, contractual, and competitive risks. A simple gate helps decide what can go where.
Classify the data first
| Class | Examples | AI tool rule |
|---|---|---|
| Public | Published research, public regulatory guidance | Any approved tool |
| Internal, non-sensitive | Aggregated delivery metrics, anonymized benchmarks | Approved business tools with appropriate terms |
| Confidential | Budgets, partner rates, unpublished results | Only tools approved for confidential data |
| Restricted | Identifiable health information, personal data, data under strict contract terms | Only systems specifically approved; usually not general AI tools |
Check vendor terms: some AI tools may retain or use inputs, while enterprise versions often have different terms. Your organization's IT and privacy teams should decide which tools are approved for which classes.
Minimize before you share
Often you do not need the sensitive detail to get the analysis:
- Aggregate. Share weekly totals instead of impression-level logs.
- Remove identifiers. Drop device IDs, IP addresses, and NPIs if the analysis does not need them.
- Mask names. Replace partner and brand names with codes.
- Round or band. Use ranges instead of exact spend figures where precision does not matter.
The NIST Privacy Framework supports this kind of data minimization.
Use safe substitution
When the analysis needs structure but not real values:
- Create a sample data set with the same columns and realistic but fake values.
- Use the AI tool to write the analysis code or formulas on the sample.
- Run the code yourself on the real data, inside approved systems.
This gets most of the productivity benefit without exposing real data.
Health data needs extra care
Campaign data can reveal health information indirectly. A segment name, a landing page URL, or a combination of fields may indicate a condition. HHS guidance on online tracking technologies and state consumer health data laws may apply. When in doubt, treat the data as restricted.
Check outputs, too
AI outputs can include data from inputs. Before sharing an AI-generated summary, check that it does not repeat sensitive details.
Practical takeaway
Post the four-class table where your team works. Before using AI on any data set, classify it, minimize it, and consider safe substitution. If the data is restricted, do not use a general AI tool.
Sources
- NIST Privacy Framework
- HHS, Use of Online Tracking Technologies by HIPAA Covered Entities
- NIST AI Risk Management Framework
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.